Radiation recall myositis resistant to conventional therapies Clinical improvement with botulinum toxin A intervention

Ahmet Basari

doi:10.52768/3067-3852/1024

July 15, 2025

Radiation recall myositis resistant to conventional therapies Clinical improvement with botulinum toxin A intervention

View at Publisher

Ask AI

Bookmark

Share

Key Points

Significant clinical improvement was observed following botulinum toxin A treatment in patients with radiation recall myositis.
The intervention notably reduced symptoms associated with myositis, indicating potential benefits beyond conventional therapies.
Gemcitabine was identified as the most common drug linked to the development of radiation recall myositis in these patients.
Continued investigation is warranted to further explore treatment options for radiation recall myositis resistant to standard care.

Implication

Observational analysis shows improved symptoms in radiation recall myositis, suggesting botulinum toxin A may provide relief.

Abstract

Radiation Recall Myositis (RRM) is a rare phenomenon that occurs after radiotherapy and chemotherapy. Gemcitabine is the most commonly implicated agent in its development.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahmet Basari (2025) studied this question.

synapsesocial.com/papers/68e962596210319498c3002a https://doi.org/10.52768/3067-3852/1024

View at Publisher

Ask AI

Bookmark

Share

Radiation recall myositis resistant to conventional therapies Clinical improvement with botulinum toxin A intervention

Key Points

Implication

Abstract

Discussion

Cite This Study

Radiation recall myositis resistant to conventional therapies Clinical improvement with botulinum toxin A intervention

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading